LLY23.BK Eli Lilly and Company
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- 0.13%
- Fundamental score
- -
Is LLY23.BK undervalued?
Graham numberThe Graham number of Eli Lilly and Company cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Eli Lilly and Company fundamental analysis
No fundamental analysis for Eli Lilly and Company yet.
Eli Lilly and Company stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and…
Full company profileFinancial statements of Eli Lilly and Company are not available yet.
Eli Lilly and Company dividends
Eli Lilly and Company has not paid dividends in the last 3 fiscal years.
Who owns Eli Lilly and Company
Ownership data of Eli Lilly and Company is not available yet.
Eli Lilly and Company company profile
- Company name
- Eli Lilly and Company
- Ticker
- LLY23.BK
- Exchange
- Thailand Exchange
- Sector
- -
- Industry
- -
- Employees
- 50,000
- Fiscal year end
- December
- Address
- Lilly Corporate Center, Indianapolis, IN, United States, 46285
- Phone
- 317 276 2000
- Website
- lilly.com
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Eli Lilly and Company management
10- Mr. David A. RicksChairman, President & CEO · born 1968
- Mr. Lucas E. MontarceExecutive VP & CFO · born 1977
- Dr. Daniel M. Skovronsky M.D., Ph.D.Chief Scientific & Product Officer and President of Lilly Research Laboratories · born 1973
- Ms. Anat Hakim J.D.Executive VP, General Counsel & Secretary · born 1969
- Mr. Jacob S. Van NaardenExecutive VP, President of Lilly Oncology & Head of Corporate Business Development · born 1985
- Mr. Donald A. ZakrowskiSenior VP of Finance & Chief Accounting Officer
- Mr. Diogo RauExecutive VP and Chief Information & Digital Officer · born 1975
- Mr. Michael CzaparSenior Vice President of Investor Relations
- Mr. Eric DozierExecutive VP & Chief People Officer · born 1967
- Mr. Ilya YuffaExecutive VP and President of Lilly USA & Global Customer Capabilities · born 1975